Study of Neural Responses Induced by Antidepressant Effects

• Status: Completed
• Trial end date: 2021-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The proposed work aims to examine the neural changes associated with fast-acting antidepressant treatments in order to develop imaging-based biomarkers of treatment response for depression.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Marta Peciña, MD PhD; University of Pittsburgh
• Treatments: Antidepressive Agents; Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• A man or woman age of 18 or older.

• Currently experiencing a depressive episode as part of Major Depressive Disorder.

• Able to tolerate lying still on your back for 60 minutes at a time.

• Have had no more than one failed antidepressant trial of adequate dose and duration.

• Have been antidepressant medication-free for at least 21 days prior to collection of imaging data (5 weeks for fluoxetine)

Exclusion Criteria:

• Are currently taking any psychiatric medication, or any potentially augmenting or sedative drugs.

• Have a history of inadequate response/tolerability to escitalopram; or history of resistant depression

• Pregnant or breastfeeding or plan to become pregnant over the duration of the study.

• Have a history (lifetime) of psychotic depressive, schizophrenic, bipolar, schizoaffective, or other Axis I psychotic disorders.

• Meet criteria for substance dependence in the last 6 months, except nicotine, or substance abuse in the last 2 months.

• Have a medical condition that contradicts treatment with escitalopram.

• Are currently receiving psychotherapy or any other treatment for your depression.